PharmaBlock Sciences Nanjing Inc Class A (300725)

Currency in CNY
54.79
+5.27(+10.64%)
Closed·
Advertisement

PharmaBlock Sciences A (SZ:300725) Annual Report

Key Ratios

P/E Ratio58.18
Price/Book2.5
Debt / Equity2.67%
Return on Equity5.14%
Dividend Yield0.57%
EBITDA330.24M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2023
01/01
2023
31/12
2024
31/12
2025
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.94%
Dividend Yield
0.57%
Industry Median 1.75%
Annualised payout
0.28
Paid annually
5-Years Growth
+29.49%
Growth Streak

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.00

Earnings

Latest Release
11/08/2026
EPS / Forecast
0.22 / --
Revenue / Forecast
551M / --
EPS Revisions
Last 90 days

FAQ

What were PharmaBlock Sciences A's earnings for the latest quarter?

PharmaBlock Sciences A (Shenzhen: 300725) reported sales revenue of 551.43 (CNY), net income of 50.56 (CNY), and EPS of 0.22 (CNY) for the latest quarter.

What was PharmaBlock Sciences A's net income for the latest quarter?

PharmaBlock Sciences A's net income for the latest quarter was 50.56.

How did PharmaBlock Sciences A's financial performance compare year-over-year in the latest quarter?

The company's revenue moved from 508.03 million CNY in the previous quarter to 551.43 million CNY in the latest quarter, and net income moved from 48.89 million CNY to 50.56 million CNY compared to the previous quarter.

What is PharmaBlock Sciences A's net profit margin on a TTM basis?

PharmaBlock Sciences A's trailing twelve months (TTM) net profit margin is 9.97%.

What is PharmaBlock Sciences A's current debt-to-equity ratio?

PharmaBlock Sciences A's total debt-to-equity ratio is 2.67%.

What is PharmaBlock Sciences A's (Shenzhen: 300725) return on investment on a TTM basis?

PharmaBlock Sciences A's trailing twelve months (TTM) return on investment (ROI) is 5.14%.

How has PharmaBlock Sciences A's total revenue grown this year?

PharmaBlock Sciences A's total revenue was 508.03 million CNY in the previous quarter and 551.43 million CNY in the latest quarter.

What is PharmaBlock Sciences A's gross margin on a TTM basis?

The PharmaBlock Sciences A (Shenzhen: 300725) trailing twelve months (TTM) gross margin is 30.11%.

What was PharmaBlock Sciences A's revenue per share for the latest quarter?

PharmaBlock Sciences A's revenue per share for the latest quarter was 6.97 (CNY).

What is PharmaBlock Sciences A's Earnings Per Share (EPS)?

The PharmaBlock Sciences A EPS is 0.94 for the Trailing Twelve Month (TTM) period.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.